Shenzhen S.E.
06:00:00 2024-04-25 pm EDT
5-day change
1st Jan Change
6.93
CNY
+1.32%
+0.43%
-40.26%
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2020
March 30, 2021 at 09:02 am EDT
NanHua Bio-medicine Co. Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 175.564 million compared to CNY 134.160 million a year ago. Operating income was CNY 18.943 million compared to CNY 16.594 million a year ago. Net income was CNY 8.154 million compared to CNY 18.806 million a year ago. Basic earnings per share from continuing operations was CNY 0.03 compared to CNY 0.06 a year ago.
Chongqing International Trust Co., Ltd. acquired 10.8% stake in Landfar Bio-medicine Co., Ltd from Shanghai Heping Dazong Equity Investment Fund Management Co., Ltd for CNY 0.03 million.
Apr. 10
CI
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-30
CI
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-29
CI
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-28
CI
Landfar Bio Medicine’s Controlling Shareholder Boosts Stake to 30%
23-04-27
MT
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-20
CI
Landfar Bio-medicine Co., Ltd completed the acquisition of additional 29% stake in Hunan Nanhua Amspring Biotechnology Co., Ltd. from Wang Yang, Luo Yi and Changsha Aishi Pulin Information Consulting Co., Ltd. for CNY 9.7 million.
22-12-09
CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-30
CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
22-07-29
CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-29
CI
NanHua Bio-medicine Co., Ltd announced that it expects to receive CNY 275.999987 million in funding from Hunan Chasing Fund Management Co., Ltd.
22-03-21
CI
NanHua Bio-medicine Co., Ltd signed a letter of intent to acquire Medicine-related assets from YanAn Bicon Pharmaceutical Listed Company.
21-12-09
CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-29
CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021
21-08-30
CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021
21-04-28
CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2020
21-03-30
CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020
20-10-28
CI
NanHua Bio-medicine Co., Ltd's Equity Buyback announced on October 29, 2019, has expired.
20-10-27
CI
Hunan Finance Industry Fund Management Co., Ltd. cancelled the acquisition of 25.58% stake in NanHua Bio-medicine Co., Ltd. from Hunan Trust Co., Ltd.
20-10-09
CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2020
20-08-27
CI
Nanhua Bio-Medicine Co., Ltd Announces Election of Jian Wang as Non-Independent Director
20-05-19
CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2020
20-04-26
CI
Shanghai Shineton Investment Co., Ltd. completed the acquisition of 54% in Hunan ProMab Biotechnologies Co., Ltd. from NanHua Bio-medicine Co., Ltd..
19-12-16
CI
Hunan Xinghui Medical Investment Management Co., Ltd. cancelled the acquisition of 10.1% stake in NanHua Bio-medicine Co., Ltd. from Shanghai Heping Large Equity Investment Fund Management Limited.
19-12-09
CI
NanHua Bio-medicine Co., Ltd announces an Equity Buyback for CNY 100 million worth of its shares.
19-10-29
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Landfar Bio medicine Co Ltd is a China-based company mainly engaged in the biomedical and energy conservation & environmental protection business. The Companyâs biomedical business includes stem cell storage and technical services, stem cell treatment research, medical instrument purchasing & sales. The Companyâs energy conservation & environmental protection business includes energy management company (EMC) contract energy management, build-transfer (BT), product sales, and sewage treatment. The Company is involved in other businesses related to aid and build project. The Company mainly conducts businesses within the domestic market.
More about the company
1st Jan change
Capi.
-40.26% 316M -17.89% 8.25B +39.20% 3.58B -39.11% 2.46B -8.06% 2.46B -7.35% 2.38B -12.61% 1.81B -19.01% 1.55B -40.66% 1.21B +7.56% 1.11B
Medical & Diagnostic Laboratories
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
LANDFAR BIO-MEDICINE CO., LTD 
